Brooklyn Investment Group
BEAM icon

Brooklyn Investment Group’s Beam Therapeutics BEAM Stock Holding History

Brooklyn Investment Group’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10
Closed -$171 – 883
2025
Q2 		$171 Buy
+10
New +$174 ﹤0.01% 3207
2025
Q1 		– Sell
-336
Closed -$8.33K – 2780
2024
Q4 		$8.33K Buy
+336
New +$8.57K ﹤0.01% 1053

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Farallon Capital Management
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Nikko Asset Management Americas
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Bellevue Group
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Brooklyn Investment Group's BEAM Position: Q3 2025 in Review

Brooklyn Investment Group sold out of Beam Therapeutics (BEAM) in Q3 2025, closing a stake of 10 shares — an estimated $171 sold.

Brooklyn Investment Group first reported a position in BEAM in Q4 2024 and held it in 2 quarters. The position peaked at $8.33K in Q4 2024. 219 funds tracked by Wall St. Rank hold BEAM as of Q3 2025.

  • Brooklyn Investment Group reported no remaining Beam Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Brooklyn Investment Group sold 10 Beam Therapeutics shares in Q3 2025, an estimated $171.
  • Brooklyn Investment Group first reported a position in Beam Therapeutics in Q4 2024 and held it in 2 quarters.
  • Brooklyn Investment Group's Beam Therapeutics position peaked at $8.33K in Q4 2024.
  • 219 funds tracked by Wall St. Rank held Beam Therapeutics as of Q3 2025.

Based on Brooklyn Investment Group's 13F filing for Q3 2025, filed 14 Nov 2025.